Genetic introduction of thyroid hormone transporter in Bood-Brain-Barrier

甲状腺激素转运蛋白在血脑屏障中的基因导入

基本信息

  • 批准号:
    11557188
  • 负责人:
  • 金额:
    $ 8.64万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
  • 财政年份:
    1999
  • 资助国家:
    日本
  • 起止时间:
    1999 至 2000
  • 项目状态:
    已结题

项目摘要

We have established adenovirus-mediated gene transfer system into cells.The coding region of LST-1 and LST-2, both of which have isolated by us have introduced into adenovirus vector, packaged, and transfected into HEK293 cell with adenovirus genomic DNA.The cells that produces homologous-recombinant shrieked and made plaque formation. After producing large scale infected medium, the recombinant adenovirus was purified by CsCl ultracentrifuge.The infection titer of the purified LST-1 and LST-2 adenoviruses were measured and the IC 50 of each virus was 1.26 and 1.48 X 10^<10> pfu, respectively.When recombinant virus was applied to cultured cell line, the LST-1 and LST-2 protein was strongly expressed within 24 hr after application. The size of the band was also confirmed by Western blot analysis. The LST-1 and LST-2 expressing mammalian cell transports various organic anions as substrates and the apparent Km value of tauro-cholate uptake is 24 micro M and 32 micro M, respectively and both of which is a comparative value of the native cells reported.The establishment of the adenovirus-mediated gene transfer system wiil lead to the various applied sysem for screening of the brain-, liver and kidney oriented drug delivery and therapeutic tools.
我们建立了腺病毒介导的细胞内基因转移系统,将我们分离到的LST-1和LST-2的编码区分别导入腺病毒载体,包装后与腺病毒基因组DNA一起转入HEK293细胞,产生同源重组的细胞尖叫并形成空斑。制备大规模感染培养基后,用氯化铯超速离心法对重组腺病毒进行纯化,测定纯化后的LST-1和LST-2腺病毒的感染滴度,IC50分别为1.26和1.48×10~(-1)和1.48×10~(-1)pfu。将重组病毒应用于培养的细胞株,在作用后24小时内LST-1和LST-2蛋白有较强的表达。Western印迹分析也证实了条带的大小。表达LST-1和LST-2的哺乳动物细胞转运各种有机阴离子作为底物,对牛磺胆酸摄取的表观Km值分别为24微米和32微米,两者都是报道的天然细胞的比较值。腺病毒介导的基因转移系统的建立将为脑、肝、肾导向的药物输送和治疗工具的筛选提供各种应用系统。

项目成果

期刊论文数量(46)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Abe T et al.: "Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1."J Biol Chem. 274. 17159-17163 (1999)
Abe T 等人:“编码人肝脏特异性有机阴离子转运蛋白 LST-1 的新基因家族的鉴定。”J Biol Chem。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Abe T., Kakyo M., Tokui T., Nakagomi R., Nishio T., Nakai D., Nomura H., Unno M., Suzuki M., Naitoh T., Matsuno S.and Yawo H.: "Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1."J.Biol.Chem.. 274. 17159-1
Abe T.、Kakyo M.、Tokui T.、Nakagomi R.、Nishio T.、Nakai D.、Nomura H.、Unno M.、Suzuki M.、Naitoh T.、Matsuno S.和 Yawo H.:“识别
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kakyo M., Sakagami H., Nishio T., Nakai D., Nakagomi R., Tokui T., Naitoh T., Matsuno S., Kondo H., Abe T., and Yawo H.: "Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide2 (oatp2)."FEBS Lett.. 4
Kakyo M.、Sakagami H.、Nishio T.、Nakai D.、Nakagomi R.、Tokui T.、Naitoh T.、Matsuno S.、Kondo H.、Abe T. 和 Yawo H.:“免疫组织化学分布和功能
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tokui T. et al.: "Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat liver organic anion transporting polypeptide, oatp2."Pharmaceutical Res.. 16. 912-916 (1999)
Tokui T. 等人:“普伐他汀是一种 HMG-CoA 还原酶抑制剂,由大鼠肝脏有机阴离子转运多肽 oatp2 转运。”Pharmaceutical Res.. 16. 912-916 (1999)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Abe T., Kakyo M., Sakagami H., Tokui T., Nishio T., Tanemoto M., Nomura H., Hebert S.C., Matsuno S., Kondo H., and Yawo H.: "Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transport thyroid hormo
Abe T.、Kakyo M.、Sakagami H.、Tokui T.、Nishio T.、Tanemoto M.、Nomura H.、Hebert S.C.、Matsuno S.、Kondo H. 和 Yawo H.:“分子特征和组织分布
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ABE Takaaki其他文献

ABE Takaaki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ABE Takaaki', 18)}}的其他基金

Drug discovery for Diabetic Nephropathy through altering gut microbiota community
通过改变肠道菌群来发现糖尿病肾病的药物
  • 批准号:
    20K20604
  • 财政年份:
    2020
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Pioneering)
Development of novel drugs for CKD
CKD新药开发
  • 批准号:
    26293031
  • 财政年份:
    2014
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Relation between 1-metyl adenosinea and rheumatoid arthritis
1-甲基腺苷与类风湿性关节炎的关系
  • 批准号:
    26305007
  • 财政年份:
    2014
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Indole analog mitochonic acid-5 (MA-5) has novel therapeutic effects on kidney injury
吲哚类似物线粒体酸5(MA-5)对肾损伤具有新的治疗作用
  • 批准号:
    26670070
  • 财政年份:
    2014
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Biomarkers for ischemia and renal faiure
缺血和肾衰竭的生物标志物
  • 批准号:
    24659062
  • 财政年份:
    2012
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Blockade of renal malignant cycle by transcriptional regulation of SLCO transporter
通过 SLCO 转运蛋白的转录调节阻断肾恶性循环
  • 批准号:
    23390033
  • 财政年份:
    2011
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of in vivo evaluation system of human organic anion transpoter
人体有机阴离子转运蛋白体内评价系统的研制
  • 批准号:
    20390043
  • 财政年份:
    2008
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Clinical application of the origanic anion transporter family
有机阴离子转运蛋白家族的临床应用
  • 批准号:
    18390045
  • 财政年份:
    2006
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional regulation and clinical application of the organic anion transporter LST family.
有机阴离子转运蛋白LST家族的功能调控及临床应用。
  • 批准号:
    16390038
  • 财政年份:
    2004
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular characterization of the organic anion transporter family
有机阴离子转运蛋白家族的分子表征
  • 批准号:
    14370777
  • 财政年份:
    2002
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似海外基金

Structure and function of the thyroid hormone transporter MCT8
甲状腺激素转运蛋白MCT8的结构和功能
  • 批准号:
    221029121
  • 财政年份:
    2012
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Priority Programmes
The relation between thyroid hormone transporter expression in the human placenta and thyroid function of premature infant
人胎盘甲状腺激素转运蛋白表达与早产儿甲状腺功能的关系
  • 批准号:
    24791104
  • 财政年份:
    2012
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Analysis of mice mutants deficient in the thyroid hormone transporter MCT8
甲状腺激素转运蛋白 MCT8 缺陷小鼠突变体分析
  • 批准号:
    117145524
  • 财政年份:
    2008
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Research Grants
Genetic introduction of thyroid hormone transporter into the Bood-Brain-Barrier
将甲状腺激素转运蛋白基因引入血脑屏障
  • 批准号:
    11557001
  • 财政年份:
    1999
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
Molecular and Physiological Characterization of Thyroid Hormone Transporter
甲状腺激素转运蛋白的分子和生理学特征
  • 批准号:
    10670111
  • 财政年份:
    1998
  • 资助金额:
    $ 8.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了